Creating new gene therapy tools for cystic fibrosis treatment
Development of AAV vectors for CF therapy
This study is working on creating better tools to deliver gene therapy for cystic fibrosis, aiming to help patients by improving how these treatments reach the lungs and work effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10747296 on NIH RePORTER |
What this research studies
This research focuses on developing advanced adeno-associated virus (AAV) vectors to improve gene therapy for cystic fibrosis (CF), a genetic disorder caused by mutations in the CFTR gene. The team aims to enhance the delivery of these vectors to airway epithelial cells by overcoming barriers that limit their effectiveness. By using innovative techniques such as directed evolution and phage display technology, the researchers hope to create AAV vectors that can better penetrate blood vessels and avoid neutralizing antibodies. This approach could lead to more effective treatments for patients with CF.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis who may benefit from advanced gene therapy techniques.
Not a fit: Patients with cystic fibrosis who have contraindications to gene therapy or those who do not have the specific CFTR mutations targeted by this research may not benefit.
Why it matters
Potential benefit: If successful, this research could provide a more effective gene therapy option for patients with cystic fibrosis, potentially improving their lung function and overall health.
How similar studies have performed: Previous research has shown promise in using AAV vectors for gene therapy, but this specific approach of systemic administration to enhance transduction in airway cells is relatively novel.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Samulski, Richard J — Univ of North Carolina Chapel Hill
- Study coordinator: Samulski, Richard J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.